Amphotericin B Liposome Injection Recalled for Subpotency Nationwide
Sun Pharmaceutical recalled Amphotericin B Liposome for Injection due to subpotent drug content. The recall involved 12,960 vials distributed nationwide across the United States.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for subpotent drug content, which presents a risk of reduced treatment efficacy. No reported illnesses or injuries are mentioned in the source. Per the severity rubric, this qualifies as High (Score 3) because it is a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Amphotericin B Liposome for Injection, 50mg/vial, has been recalled by Sun Pharmaceutical Industries, Inc. due to subpotency in the affected batches. The product is manufactured by Sun Pharmaceutical Medicare Limited in India and distributed from the company's New Jersey facility.
The affected lots are Lot BAD0089A (expiration 01/2025) and Lot BAD0330A (expiration 07/2025), NDC 62756-0233-01. Approximately 12,960 vials were distributed nationwide to hospitals and healthcare facilities across the United States.
The recall was initiated on May 30, 2023, and was terminated as of December 18, 2023.
The recalled product
- Product
- Amphotericin B Liposome for Injection, 50mg/vial, Rx only, Distributed by Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by Sun Pharmaceutical Medicare Limited, Baska Ujeti Road, Ujeti, Halol-389350, Gujarat, India, NDC 62756-0233-01
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Injectable Pharmaceutical
- Hazard
- subpotent
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # BAD0089A
- Exp 01/2025
- BAD0330A
- Exp 07/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27